An ongoing dialogue on HIV/AIDS, infectious diseases,
December 22nd, 2012
Chaos in the Diagnosis of C diff, and Dogs are Amazing Creatures
If you’re confused about the best way to diagnose C diff these days, welcome to the club. There are all kinds of tests out there, and no uniform approach between labs. Our lab actually does three tests — and will do a fourth (the classic cytotoxicity assay) if you request it. The result? Chaos, confusion, […]
December 20th, 2012
Severe Telaprevir Rashes and Waiting (or Not Waiting) to Treat Hepatitis C
Yesterday, the FDA issued a drug safety alert about severe rashes — “some fatal” — in patients treated for HCV with interferon, ribavirin, and telaprevir. The culprit, of course, is the telaprevir. The label already contained warning information about serious skin rashes with the drug, and this alert serves to heighten our awareness of the […]
December 17th, 2012
On Service — But Some Works in Progress
When several of my colleagues attend on the inpatient consult service, they turn on an “out of office” message that provides an automated e-mail reply that goes something like this: I am currently attending on the inpatient consult service. During this busy time, I may not be able to respond to email in a timely […]
December 5th, 2012
Top HIV Stories of 2012
Somewhere in our genome, we are programmed to use the end of the year as a time to reflect on the previous 12 months — and to make lists! If you don’t believe me, there’s barely a publication or web site out there that hasn’t already succumbed, and we’re just in early December. And what […]
November 28th, 2012
A Complicated Curbside Consult I Won’t be Doing — But One Day Might Have To
From a local primary care provider comes this email: Any chance you can look at my notes and scanned outside records from 6/22/2010 till today (including Nov 6 notation that details extensive past evaluation, including two previous ID consults) and labs? Briefly: 72 yr old woman with 6 episodes over the last 4 years of […]
November 8th, 2012
Steroids for Bell’s Palsy and the ID Doctor
OK, let’s imagine you’ve just gotten a call/email/text from one of your colleagues about Bell’s palsy; he/she is a busy PCP who periodically asks you very reasonable ID questions. I suspect it went something like this: COLLEAGUE: Hi Friendly ID Doctor, quick question — I have a patient with Bell’s palsy — wondering whether to […]
November 7th, 2012
Vitamins and the Department of Bad Timing
Now that the election is over, we can get back to something that really matters — namely vitamins, and specifically whether they really help people. Last month there was a large, well-done study from Tanzania showing that mega-doses of vitamins not only didn’t help those HIV starting ART, but they actually were harmful — LFTs […]
November 2nd, 2012
Antiretroviral Rounds: Resistance on Two Fronts
Got this challenging curbside consult from a colleague, and it has a interesting wrinkle: I have a longstanding patient with HIV who had many failed regimens in the 1990’s with resultant following mutations on a genotype done in 2003: NRTI (M184V, Q151M mutations); PI (A71, I54V, K20M, L10I, L90M, V82A mutations); no NNRTI resistance. She has been undetectable since […]
October 22nd, 2012
Can a “Treat Everyone with HIV” Policy Actually Work? In San Francisco, Yes
As has often been the case in the history of the HIV epidemic, the HIV/AIDS Division at San Francisco General Hospital and the San Francisco Department of Health were ahead of the curve in 2010 when they issued a recommendation that all people with HIV should receive treatment, regardless of CD4 count. Of course, US guidelines […]
October 17th, 2012
It’s Time to Tell Our Patients to Stop Their Vitamin Supplements
Over in JAMA, there’s a large study out today that (yet again) failed to demonstrate a benefit of vitamins. Over 3000 patients with HIV in Tanzania were randomized to receive either high-dose or standard-dose multivitamin supplementation, in addition to “HAART” (ugh). Though the study was planned for 24 months, it was stopped early by the Data […]

